**Please do not contact me via DM with clinical or professional queries - contact my PA at sarcoma.medsecchelsea@rmh.nhs.uk**

Thank you so much for your trust and support, my dear friends in Albania🙏😊 As you well said, together for every child 🤝✊️🌐 Geography must not decide who lives ✊️

🏆 Honouring the legacy of Christopher Fletcher (1958–2024). A pioneer in tumor pathology and a dedicated mentor, his influence lives on through the knowledge he shared and the people he inspired. 🔬 ow.ly/aJK350ZZjAb #Pathology

Voting for the @ASCO Election is now open 🗳️. I am honored to be running as one of the candidates for the #NominatingCommittee. Visit asco.org/election to learn more about the candidates and place your vote! @CUHKMedicine @apoddc @APCLC_2023 @ctosociety @IASLC @LungPolicy @CUHKofficial

On a beautiful crisp autumnal London morning, am reflecting on the major practice-changing and development datasets presented @myESMO #ESMO26, the strong @royalmarsdenNHS & @ICR_London faculty leadership, & above all the global friends & colleagues who are making a difference

#ESMO26 🧬 PEAK | Phase III 👥 Advanced GIST after imatinib 💊 Bezuclastinib + sunitinib vs sunitinib 📈 mPFS: 16.5 vs 9.2 mo (HR 0.50) 🎯 ORR: 45.6% vs 25.8% 🔄 After SUN progression (n=128): 📈 mPFS: 7.4 mo | ORR: 29.7% 🚀 Sustained activity despite prior SUN progression! @OncoAlert

🧬 #ESMO26 | Phase III ARTEMIS-011 highlights a promising advance in relapsed/refractory osteosarcoma after ≥2 prior treatment lines. Risvutatug rezetecan, a B7-H3–directed ADC, improved median PFS versus gemcitabine/docetaxel (5.5 vs 1.4 months; HR 0.33; p<0.0001). This represents a 67% reduction in the hazard of progression or death, with higher disease control rates (76% vs 33%). However, grade ≥3 treatment-related adverse events were frequent (93% vs 83%), and overall survival data remain immature. A meaningful step forward in a disease with limited therapeutic options, pending mature survival and safety data. #LBA9 #Sarcoma

New at #ESMO26: faridoxorubicin (AVA6000) data in salivary gland cancers show a median PFS of 11.4 months, with FAPI-PET imaging showing FAP persists as tumors respond. Poster 1549P, 12:00-12:45 PM CET. avacta.com/faridoxorubicin-t… #preCISION #AVCT

At #ESMO26, Piotr Rutkowski (@rutkowskip1972) discusses a detailed safety analysis of varegacestat for desmoid tumors in the phase 3 RINGSIDE trial, how it compares with nirogacestat, and managing long-term toxicity @myESMO #Sarcoma #DesmoidTumors

RT @ManuPalmerini: #emactuzumab #tenosynovialgiantcelltumors ORR 29.3% TVS 53.8% PROs improvement Congratulation to @hansgelderblom and…

Congratulations to Dr. Ajay Gopal on receiving the Oliver Press Award for Extraordinary Mentorship. Gopal continues the legacy of the late Dr. Oliver Press through mentorship that spans disciplines, career stages and institutions. bit.ly/4syL1z6

@RobinL_Jones presented the #Phase3 #Peak crossover: Bezuclastinib + sunitinib combination following sunitinib monotherapy in patients with GIST. Improved ORR (20.3 vs. 29.7%) and duration of response (5.7 vs 7.4m) in pts who were crossed over from #sunitinib to #bez+sunitinib. #GIST #sarcoma #ESMO26 @myesmo @ctosociety #ESMOAmbassadors

Fantastic presentation of the PEAK trial by Prof R Jones @RobinL_Jones in #ESMO2026 @myesmo about the results of patients with crossover to bezuclastinib +sunitinib from the Suni arm. 56%ORR and PFS 7.4 m (longer than in previous Suni line?!! a new combo alternative is here!

#ESMO26 #GIST: three nice abstracts tackling the same problem (polyclonal resistance) from different angles. Resistance after imatinib is a mosaic of secondary KIT mutations and no approved KIT inhibitor addresses them all. Kudos to Dr. @RobinL_Jones, Dr Bauer, Dr Chi and Dr @dileo_palma for an excellent session. Great discussion by Dr. Dileo. 🔹 PEAK crossover bezuclastinib + sunitinib (SUT) after PD on 2L SUT: • ORR 29.7% (56% if best response to SUT was PD); • mPFS 7.4; • Gr≥3 TRAEs 39%, discontinuation 2.3% Caveat: non-randomized, benefit drops from the historical 16.5 mo upfront to 7.4 mo after SUT failure. 🔹 NB003 - final analysis of ph1 (n=158): • ORR 46.7% in 3L and 45.7% in 4L, 12.5% in ≥5L • mPFS 13.8 mo (3L), 11.0 mo (4L), 3.9 mo (≥5L) • Responses across a variety of secondary mutations in ABP and AL. Caveat: predominant Asian representation (67%), Gr≥3 anemia 55%, CPK rise 49%. Phase 3 GISTAR-1 (vs. Rego) will provide more definitive efficacy data in the 3rd-line setting, but will only accrue in Asia. 🔹 StrateGIST-1 —> longitudinal ctDNA analysis: • Detectable baseline ctDNA: PFS 7.3 vs 16.6 mo (HR 0.39) • Clearance (>99% drop in maxVAF) at wk 2/4/8: HR 0.51/0.65/0.57 • Mutation-agnostic maxVAF outperformed mean VAF and Guardant360 score Caveat: exploratory, landmark bias, not shown independent of imaging or tumour burden. Hypothesis-generating. 💡 Take-Home: 1. Broader KIT coverage is the shared goal, and treating earlier is likely better. 2. Combination vs single broad-spectrum agent is unresolved, with different toxicity trade-offs (and access/costs, once these drugs start getting approved). 3. ctDNA could serve all three strategies, as an early efficacy readout, for response-adapted treatment and for trial enrichment, but needs prospective validation. #ESMO2026 #ESMOAmbassadors @myESMO #GIST

Fantastic to see colleagues, friends @myESMO #ESMO26 united in our vision to tackle cancer & improve outcomes globally! @ASCOPres @MyriamChalabi @RebeccaDSing @DrChoueiri @tompowles1 @PBarataMD @amanda_psyrri @ProfSyedHussain @VivekSubbiah @StephenVLiu @OncoAlert @dr__mukherji

Amazing discussion of Prof Robin Jones @RobinL_Jones in #ESMO2026 @myESMO. Clear concepts and sharp analysis. To enjoy it!!

Caught him alive 😁! @StephenVLiu Always great to meet up. #ESMO26 #ESMOAmbassadors

Important Radiology Signs

🙌 #ESMO26: F. André, Y. Janjigian, J. Larkin and N. Harbeck welcome you to the ESMO Congress 2026, your international, multidisciplinary oncology congress. Join us to explore the latest innovations to improve patient outcomes. 🔗 ow.ly/WKpA50ZXVSl #esmomeetings

Nice summary of data on ADCs in #sarcoma by @breelynwilkyMD . I especially like the take-home message: “there’s a lot we don’t know about ADC patient selection in solid tumors, and in sarcoma this challenge is even more pronounced” Still, promising data with HER2ADC in DSRCT and B7H3 in osteosarcoma (including a phase III to be presented monday) #ESMO26 @myESMO @ctosociety